GelMEDIX Inc. and Catalent, Inc. have announced a global partnership aimed at advancing regenerative therapies designed to restore vision in patients with ocular and retinal diseases. The collaboration will combine GelMEDIX’s therapeutic research programs with Catalent’s expertise in manufacturing induced pluripotent stem cells (iPSCs) and cell-based therapies.
The agreement focuses on supporting the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies. Through the partnership, the biotechnology company will gain access to Catalent’s Good Manufacturing Practice (GMP)-compliant iPSC cell lines as well as its specialized manufacturing infrastructure for cell therapy development.
Induced pluripotent stem cells are adult cells that have been reprogrammed into a stem-like state, enabling them to develop into a wide variety of specialized cell types. In regenerative medicine, iPSCs are considered a promising platform because they can potentially replace damaged or diseased cells in the body. Researchers are increasingly exploring their potential to treat degenerative eye conditions that lead to progressive vision loss.
Under the terms of the collaboration, Catalent will provide GelMEDIX with access to its proprietary, off-the-shelf iPSC lines that meet global GMP standards. The company will also support GelMEDIX with a range of development and manufacturing services, including process development, analytical testing, scale-up of production, and full GMP manufacturing for clinical trials.
Catalent’s role in the program will extend across multiple stages of development. The company will help guide the production and optimization of iPSC-derived therapies from early laboratory development through clinical manufacturing, supporting GelMEDIX’s transition from research into human clinical studies.
David McErlane, Biologics Group President at Catalent, said the partnership reflects the company’s commitment to supporting innovative therapeutic programs. He noted that Catalent’s experience in cell therapy development and manufacturing positions the company to help accelerate next-generation treatments for serious eye diseases.
“We are proud to work with GelMEDIX to support this important clinical program targeting ocular and retinal diseases,” McErlane said, adding that the collaboration aims to help bring transformative therapies to patients in need.
Max Cotler, Chief Executive Officer of GelMEDIX, described the agreement as a key milestone for the company’s development pipeline. According to Cotler, working with a specialized manufacturing partner early in the development process will help accelerate progress toward clinical trials for the company’s lead regenerative therapy programs.
GelMEDIX is focused on developing treatments designed to repair or replace damaged cells in the eye, potentially restoring vision for patients affected by degenerative retinal disorders. Many of these conditions currently have limited treatment options and can lead to permanent vision impairment or blindness.
By combining GelMEDIX’s regenerative therapy platform with Catalent’s established capabilities in iPSC development and cell therapy manufacturing, the two companies aim to streamline the pathway from laboratory research to clinical application.
Catalent is widely recognized as a major contract development and manufacturing organization (CDMO) serving the global pharmaceutical and biotechnology industries. The company provides development, manufacturing, and supply chain solutions for biologics, gene therapies, and advanced cell therapies.
The new collaboration highlights the growing interest in stem cell–based regenerative medicine and its potential to address diseases that currently have few effective treatments. If successful, GelMEDIX’s iPSC-derived therapies could represent an important step forward in restoring vision for patients suffering from serious ocular and retinal disorders.